Effectiveness of MVA-BN vaccination in a population at high-risk of mpox: a Spanish cohort study.
Mario Fontán-VelaVictoria HernandoCarmen OlmedoErmengol ComaMontse MartínezDavid Moreno-PerezNicola LorussoMaría Vázquez TorresJosé Francisco Barbas Del BueyJavier Roig-SenaEliseo PastorAntònia Galmés TruyolsFrancisca Artigues SerraRosa María Sancho MartínezPello Latasa ZamalloaOlaia Pérez MartínezAna Vázquez EstepaAmós José García RojasAna Isabel Barreno EstévezAlonso Sánchez-Migallón NaranjoJaime Jesús Pérez MartínPilar Peces JiménezRaquel Morales RomeroJesús CastillaManuel García CenozMarta Huerta HuertaAn Lieve Dirk BooneMaría José Macías OrtizVirginia Álvarez RíoMaría Jesús Rodríguez RecioMaría Merino DíazBelén Berradre SáenzMaría Teresa Villegas-MorenoAurora LimiaAsuncion DiazSusana Mongenull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.